

Supplementary Table 1

## Characteristics of RCT and non-RCT cohort

	RCT cohort (n=136)	Non-RCT cohort (n=160)	p value
Background characteristics			
Age: mean $\pm$ SD	59.0 $\pm$ 12.5	61.3 $\pm$ 13.4	0.133
Man: n (%)	41 (30.1)	45 (28.1)	0.800
Previous SAH: n (%)	9 (6.6)	20 (12.5)	0.134
Previous hemorrhagic stroke: n (%)	1 (0.7)	8 (5.0)	0.073
Previous ischemic stroke: n (%)	3 (2.2)	16 (10.0)	0.013
Risk Factors: n (%)			
Hypertension	60 (44.1)	81 (50.6)	0.317
Diabetes	8 (5.9)	8 (5.0)	0.939
Dyslipidemia	45 (33.1)	52 (32.5)	1.000
Smoking habit	25 (18.4)	18 (11.2)	0.116
Target aneurysm, maximum diameter (mm): mean $\pm$ SD	7.02 $\pm$ 2.62	8.61 $\pm$ 4.72	0.001
Radiographic outcome: n (%)			
Complete occlusion	49 (36.0)	59 (36.9)	
Neck remnant	49 (36.0)	48 (30.0)	
Aneurysm filling	38 (27.9)	53 (33.1)	
Initial combination of antiplatelet drugs: n (%)			
ASA+ CLP	134 (98.5)	120 (75.0)	0.108
ASA+CLP+CLZ	2 (1.5)	22 (13.8)	
ASA+CLP+PRG	0 (0.0)	3 (1.9)	
ASA+PRG	0 (0.0)	11 (6.9)	
CLP+CLZ	0 (0.0)	1 (0.6)	
ASA only	0 (0.0)	3 (1.9)	

Abbreviations: RCT, randomized control trial; SD, standard deviation; SAH, subarachnoid hemorrhage; ASA, acetylsalicylic acid (aspirin); CLP, clopidogrel; CLZ, cilostazol; PRG, prasugrel

## Supplementary Table 2

## Continued antiplatelet drug in reducing from DAPT to SAPT

	Long term DAPT (n=191)	Short term DAPT (n=105)	P value
Patient reducing to SAPT: n (%)	161 (84.3)	104 (99.0)	<0.001
Antiplatelet drugs after reducing to SAPT: n (%)			0.340
Aspirin	81 (50.3)	58 (55.8)	
Clopidogrel	63 (39.1)	41 (39.4)	
Cilostazol	15 (9.3)	5 (4.8)	
Prasugrel	2 (1.2)	0 (0.0)	

Abbreviations: DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy

## Supplementary Table 3

Platelet aggregation study (Verify Now™) at registration and 6 and 12 months after SACE

	Long term DAPT (n=191)				Short term DAPT (n=105)			
	n	Median	Q1	Q3	n	Median	Q1	Q3
ARU								
Registration	243	435.0	403.0	506.0	148	429.0	397.0	505.0
6 months	100	456.0	396.5	513.5	60	502.0	431.0	612.0
12 months	83	430.0	400.0	525.0	55	516.0	421.0	618.0
PRU								
Registration	244	178.0	121.0	218.0	152	177.5	129.0	225.0
6 months	100	165.5	119.5	202.0	59	221.0	171.0	260.0
12 months	84	171.5	125.0	235.0	57	211.0	166.0	257.0

Abbreviations: SACE, stent assisted coil embolization; DAPT, dual antiplatelet therapy; ARU, aspirin reaction units; PRU, P2Y12 reaction units

## Supplementary Table 4

Relation between timing from DAPT to SAPT and events

## Ischemic stroke

Event number	Group	Duration from SACE to event (days)	Situation of antiplatelet therapy at event	Duration from starting of SAPT to event (days)
1	long term DAPT	11	DAPT	NA
2	long term DAPT	24	DAPT	NA
3	long term DAPT	216	SAPT	13
4	long term DAPT	371	DAPT	NA
5	long term DAPT	391	DAPT	NA
6	long term DAPT	394	SAPT	28
7	short term DAPT	6	DAPT	NA
8	short term DAPT	10	SAPT	10
9	short term DAPT	20	DAPT	NA
10	short term DAPT	97	SAPT	9

## Hemorrhagic event

Event number	Group	Duration from SACE to event (days)	Situation of antiplatelet therapy at event	Duration from event to starting SAPT (days)
1	long term DAPT	184	DAPT	NA
2	long term DAPT	374	DAPT	1
3	short term DAPT	35	SAPT	NA
4	short term DAPT	40	DAPT	2
5	short term DAPT	60	DAPT	2
6	short term DAPT	230	SAPT	NA

Abbreviations: SACE, stent-assisted coil embolization; DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy; NA, not applicable